Sep 8, 2026 · 30 min
AI stocks show strength as market breadth deteriorates
AI Stocks Lead, Blue Chips Lag In Down Session: AMD, Magnite, TVTX In Focus
The episode weighs whether resilience in semiconductors can offset worsening breadth, blue-chip weakness, rising oil prices, and elevated Treasury yields.
- 1Major indexes weakened as blue-chip and software stocks fell, with the S&P 500 approaching its 21-day line and the Dow breaking below its 50-day average.
- 2AMD’s nearly 6% rally signals semiconductor strength, but the hosts stress that confirmation is needed before increasing market exposure.
- 3Magnite and Travere Therapeutics present distinct technical setups, supported by improving business momentum and strong earnings-related gaps.
Don't miss
AMD rallies nearly 6% on strong volume and breaks out of a short downtrend, even as the broader market remains under pressure.
The brief
Alissa Coram and Ken Shreve open with a broad market decline driven by rising oil prices, elevated Treasury yields, and weakness in blue-chip and software stocks.
The headline indexes deteriorate as the S&P 500 moves toward its 21-day line, the Dow breaks its 50-day average, and market breadth weakens through RSP and QQQE.
AMD rallies nearly 6% on strong volume and breaks out of a short downtrend, offering evidence of AI and semiconductor strength without confirming that the market is clear.
Magnite’s earnings-related gap, accelerating growth, improving relative strength, and proximity to prior highs make its advertising-platform setup one of the episode’s key watch points.
Travere Therapeutics shows a strong earnings gap, a reversal at the 21-day line, and tight weekly action, while its approved kidney treatment supports a path to profitability.
The central takeaway is restraint: resilient AI names matter, but further oil-price gains, elevated yields, and deteriorating breadth argue for confirmation before increasing exposure.
What was said on this episode
14 statements · 7 positive · 7 negative
The Nasdaq’s mild decline is not decisively bearish.
“not a decidedly bearish day by any means for the NASDAQ”
Listen at 3:50
Amgen’s cardiovascular drug will likely produce a Novartis-like trial readout.
“it's likely that Amgen's drug is probably going to give a similar readout”
Listen at 6:05
The S&P 500 should test and hold its 21-day line this week.
“We'd like to see it ultimately kind of test and hold the 21-day line this week.”
Listen at 8:27
The Fed will probably raise rates 25 basis points at its September meeting.
“It's probably about a 60% chance that the Fed is going to move up by a quarter point at the September 15th, 16th meeting.”
Listen at 10:23
Small-cap stocks are lagging and trading below their 50-day average.
“small caps are lagging, no doubt about it, and starting to live below that 50-day line”
Listen at 11:12
WTI reaching $100 would be harmful for the stock market.
“if we do keep marching towards $100, I can't believe that's going to be good for the market.”
Listen at 13:06
Higher oil prices and Treasury yields remain major market headwinds.
“higher oil prices and higher yields is still a formidable headwind here”
Listen at 14:00
Market breadth was less than two-to-one negative on both exchanges.
“overall breadth, it wasn't more than two to one negative on both exchanges today. It was less than two to one negative on both exchanges.”
Listen at 15:13
AMD’s breakout was an aggressive buy for traders.
“it was an aggressive buy for traders”
Listen at 17:19
Investors should avoid haphazardly buying AI stocks after the rally.
“you want to be careful. You don't want to be just kind of haphazardly buying”
Listen at 21:04
Magnite is forming a constructive consolidation base.
“it's a nice little base setting up here”
Listen at 23:15
Magnite may be in the early stages of an upward move.
“I think this one is still, could be in the early stages of a move here”
Listen at 24:07
Travere Therapeutics is technically a very healthy stock.
“this is just technically a very healthy stock”
Listen at 25:53
Travere Therapeutics offered an aggressive entry at its 21-day line.
“I think you had an aggressive entry today off of the 21-day line. I think you could have entered the stock today.”
Listen at 27:35
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.